How patient input has impacted integrated drug delivery system development

Published: 27-Jan-2017

Largely because of the popularity of self-administered therapies for rheumatoid arthritis, diabetes and other chronic conditions, the market demand for integrated delivery systems — which combine an injectable drug, its container and the system used to administer it — continues to grow

You need to be a subscriber to read this article.
Click here to find out more.

The increase in self-administered drugs is part of an even larger shift towards a more patient-centric approach to the production of integrated delivery systems.

Because of this renewed focus on the patient, drug delivery system manufacturers are continually re-evaluating the processes by which they improve existing systems and how they develop new ones.

As a result, delivery system manufacturers have become an invaluable partner to pharmaceutical companies.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like